Imprimis Pharma (IMMY) Reports Q3 Loss of $0.28, Miss on Revenues
Imprimis Pharma (NASDAQ: IMMY) reported Q3 EPS of ($0.28), versus $0.00 reported last year. Revenue for the quarter came in at $6.5 million versus the consensus estimate of $6.86 million.
Third Quarter 2017 and Recent Financial Highlights:
- Gross ophthalmology-related revenue of $4.9 million, up over 60% year-over-year
- 503B revenue up to $2.6M for the quarter, up 14% quarter-over-quarter
- Average 503B order exceeded $1,300 for the quarter
- 503B gross margin exceeded internal target of 60%
- Revenue of $6.5 million, up 34% year-over-year
- Adjusted EBITDA loss of $1.6 million, a 45% improvement year-over-year
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.